Treatment Recommendations for aHUS

The following chart is a simplified representation of the recommended  therapeutic options for aHUS from Zuber et al.’s 2012 paper, Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.

To access a slide containing the full, detailed chart, please click here.

To download the PDF version of aHUS Canada’s simplified chart (seen below), please click here.

Treatment Recommendations for aHUS - March 2015

[1] Chart adapted from Zuber, J. et al. Nat. Rev. Nephrol. 8, 643–657 (2012); published online 2 October 2012; doi:10.1038/nrneph.2012.214
[2] Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V on behalf of the French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012:8:643-657.
[3] Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267-1279.
[4] Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010:36(6):673-681.
[5] Noris M and Remuzzi G. Review Article: Atypical Hemolytic–Uremic Syndrome. N Engl J Med 2009;361:1676-87.
[6] Bresin E, Daina E, Noris M, et al. Outcome of renal transplantation in patients with non–Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol. 2006;1:88-99.
[7] Legendre C.M., Licht, C., Muus P. et al. Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome. N Engl J Med 2013;368:2169-81.